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Highlights
We find extracellular matrix protein versican 1 is in creased by cigarette smoke extract solution in lung 
fibroblasts.
Versican 1 knockdown restore cigarette-related elastin loss through chondroitin sulfate decrease.
Exgenous chondroitin sulfate could block the beneficent effect brought by versican 1 knockdown.
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sulfate (CS) matrix proteoglycan versican 1 (V1). V1 is a known inhibitor of elastic fiber 
deposition and this study investigates the effects of knockdown of V1, and add-back of CS, on 
CCL-210 lung fibroblasts treated with cigarette smoke extract (CSE) as a model for COPD. CSE 
inhibited fibroblast proliferation, viability, tropoelastin synthesis, and elastin deposition, and 
increased V1 synthesis and secretion. V1 siRNA decreased V1 and constituent CS, did not affect 
tropoelastin production, but blocked the CSE-induced loss in insoluble elastin. Exogenous CS 
reduced insoluble elastin, even in the presence of V1 siRNA. These findings confirm that V1 and 
CS impair the assembly of tropoelastin monomers into insoluble fibers, and further demonstrate 
that specific knockdown of V1 alleviates the impaired assembly of elastin seen in cultures of 
pulmonary fibroblasts exposed to CSE, in icating a regulatory role for this protein in the 
pathophysiology of COPD.
Key words: pulmonary fibroblast, COPD, elastin, versican
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pt1. IntroductionCOPD is characterized by persistent airway inflammation, irreversible airway obstruction and 
airway and parenchymal structural remodeling. Recurrent acute and chronic airway inflammation 
destroys lung tissue gradually, leading to air sac enlargement and eventually emphysema. 
Elastin is an essential structural protein in the lung extracellular matrix (ECM) of alveolar walls, 
ensuring elastic recoil and compliance (Maclay et al., 2012). Elastases (Metalloproteinases) from 
inflammatory cells, chiefly neutrophils and macrophages, degrade elastin and other connective 
tissue components, leading to development of balloon-like bullae or blisters that trap air, thereby 
giving rise to emphysema. Biochemical studies of dissected lung tissue show decreased 
expression of elastin in both centrilobular and panacinar emphysema (Snider, 2000). This 
widespread loss of elastin, which is reflected in reduced lung function, however, is not balanced 
by repair despite evidence that the lung fibroblasts retain their ability to synthesise tropoelastin 
(Zhang et al., 2012).
During elastic fiber formation, tropoelastin is secreted at the cell surface, complexed with an 
elastin binding protein that mediates delivery of tropoelstin onto an elastin microfibrillar scaffold 
where it is cross-linked to form insoluble elastin. Several studies have shown chondroitin sulfate 
(CS) rich matrix proteoglycans, such as versican, inhibit this process (Hinek et al., 1991; Hinek et 
al., 2000; Huang et al., 2006; Black et al., 2008), and COPD lungs may also have increased 
content of CS proteoglycans in alveolar walls (Deslee et al., 2009). 
Versican is a large ECM proteoglycan present in most tissues, secreted by numerous cells 
including lung fibroblasts, and interacting with various binding partners (Wight, 2002; Wu et al., 
2005). The amino terminal globular end (G1) is characterized by a hyaluronan binding region. 
The carboxyl terminal globular domain (G3) consists of epidermal growth factor like domains, 
carbohydrate recognition domain and complement binding domain. Alpha and beta core protein 
domains between two globular terminals covalently link to CS glycosaminoglycan (GAG) chains. 
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There are at least four splice variants of versican, named V0, V1, V2, V3, which differ in the size 
of their core proteins generated by alternative splicing of mRNA encoding the two GAG chain 
binding domains. V0 and V1 are distributed widely in adult tissues, in which V1 is the principal 
proteoglycan found in pulmonary ECM (Sampson et al., 1984). V2 seems to be expressed only in 
the central nervous system (Wu et al., 2005; Dours-Zimmermann et al., 2009). The V3 variant, 
which lacks GAG domains and thus CS chains, is generally expressed at very low levels in adult 
tissues (Cattaruzza et al., 2002). This complex structure of versican and its variants underlies 
multiple effects on proliferation, adhesion, locomotion and interactions with ECM components. 
Several studies within the past decade have confirmed a significant role for V1 in regulating local 
cell interactions, and ECM metabolism (Wight, 2002; Wu et al., 2005). The carboxyl terminal G3 
domain interacts with 1 integrin, activating focal adhesion kinase, thus promoting cell adhesion 
in for example glioma cells (Wu et al., 2002). Moreover, versican binds with CD44 through its 
GAG domain or G1 hyaluronan binding domain to promote cell proliferation, migration, adhesion 
and enhanced tumor spread (Yang et al., 1999; Ang et al., 1999). Versican also modulates other 
ECM components. Notably, the isoforms of versican containing CS, or CS alone (Hinek et al., 
2000), inhibit elastin deposition at the cell surface, by inhibiting elastin binding protein-mediated 
assembly of tropoelastin (Hinek et al., 2000). Conversely, forced expression of V3, without CS 
chains, enhances elastin deposition (Merrilees et al., 2002) and concomitantly reduces 
pericellular versican (Schonherr et al., 1991). Similarly, knockdown of the isoforms containing CS 
by versican antisense also results in increased deposition of insoluble elastin (Huang et al., 
2006). These findings indicate that control of versican could provide a potential therapeutic 
strategy for maintaining or enhancing elastin deposition in COPD lung.
Considering the information aforementioned, and cigarette smoking is the leading independent 
risk factor for COPD, we hypothesize that cigarette smoking might lead to loss of COPD elastin 
through versican variation, and this effect is connected with CS changes. Main isoform of 
versican family expressed in lung is V1, and clinical specimen of COPD patients’ lungs show 
progressively increased immuno-staining for V1 and correspondingly decreasing values of FEV1. 
There are urgent needs to investigate what would happen after V1 knockdown. In this study, we 
report that insoluble elastin deposit is devastated by exposure to cigarette smoke extract (CSE), 
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and V1 expression is stimulated by CSE. V1 knockdown in lung fibroblasts overcomes elastin 
decrease caused by CSE. This beneficial effect is lost by exposure of cells to CS.
2. Materials and Methods
2.1. Cell culture and reagents
Human lung fibroblast cells (CCL-210) were obtained from American Type Culture Collection, 
(Rockville, MD, USA). Fibroblasts were cultured in DMEM supplemented with 10% FCS, 
penicillin and streptomycin (100 ng/ml) at 37°C and 5% CO2. Cells were treated with CSE (1 and 
10%), and with versican siRNA (Invitrogen, CA, USA) and/or CS (Sigma, St Louis, MO, USA). 
Kentucky reference cigarettes (2R1, University of Kentucky, KY, USA) were used to produce the 
CSE. Smoke from 3 2R1 cigarettes was thoroughly bubbled through 10 ml culture medium 
(Muller, 1995), and medium containing CSE was freshly made before each experiment.
2.2. Cellular proliferation and viability
Cell proliferation and viability were measured using the Alarma Blue (AB) colorimetric assay 
(Invitrogen, CA, USA) (Al-Nasiry et al., 2007). Briefly, fibroblasts were seeded at 2,000/well into 
96 well plates and treated with CSE medium diluted to provide a range of concentrations from 0 
to 20%. AB was added at a final concentration of 10% and over 24h, the %AB reduction 
measured. Proliferation was calculated as ratio target reading/baseline reading. Viability was 
calculated as the percentages of living cells in treated cultures to those in untreated cultures.
2.3. Quantification for elastin
Cells were seeded at 50,000 cells/well in 6-well plates and cultured for 3 and 14 days. 
Supernatants were collected for measurement of soluble elastin. Cell layers were collected for 
measurement of insoluble elastin. For both soluble and insoluble elastin, elastin levels were 
determined using the Fastin Elastin Assay Kit from Biocolor (Carrickfergus, County Antrim, UK).
2.4. Real-time PCR
Briefly, total RNA was extracted using Trizol Reagent (Invitrogen, CA, USA) and 1μg of total RNA 
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was transcribed. The relative mRNA expression of target genes in each sample were quantified 
and normalized to the GAPDH mRNA levels by the 2-Ct method (Fink et al., 1998). Fold 
difference was calculated as ratio target gene in experimental/control-1. The primer pairs used 
were as follows: elastin(forward primer) 5’-TCT GAG GTT CCC ATA GGT TAG GG-3’, (reverse 
primer) 5’-CTA AGC CTG CAG CAG CTC CT-3’; V1 (forward primer) 5’-CCC AGT GTG GAG 
GTG GTC TAC-3’, (reverse primer) 5’-CGC TCA AAT CAC TCA TTC GAC GTT-3’.
2.5. ELISA
For ELISA analyses, a V1 kit from MYBiosource (Vancouver, B.C., CA) was purchased. The level 
of V1 in culture supernatants was determined according to the manufacturer's instructions.
2.6. siRNA transfection
The sequence 5’-GAG GCT GGA ACT GTT ATT A-3’ had the best efficacy of 3 sequences tested 
and was chosen for the studies. Real-time PCR and ELISA were used to evaluate the 
knockdown effect 24h after siRNA transfection. Transfection was achieved by LipofectaminTM
2000 (Invitrogen, CA, USA), siRNA concentration was 80nM.
2.7. CS stimulation 
CS was used at concentrations ranging from 0-400g/ml and applied to the culture medium 
alone or in combination with the siRNA (80nM) and CSE (10%). Continuous concentration 
gradient CS was added in culture medium for 14 days, cells were collected and insoluble elastin 
was tested. The concentration (200g/ml) that had best efficacy was chosen to stimulate cells in 
combination with siRNA and CSE for 14 days, insoluble elastin was detected again.
2.8. Statistics
All statistical analyses were performed using GraphPadPrism v5.0. All data were expressed as 
mean±SD, and one-way analysis of variance followed by Bonferroni post-test performed to 
determine whether differences between groups were statistically significant. Differences were 
considered significant at the level of p< 0.05.
Page 7 of 21
Ac
ce
pte
d M
an
us
cri
pt
3. Results
3.1. Inhibition of fibroblast proliferation, viability, tropoelastin synthesis and insoluble elastin by 
CSE
Cells were treated with CSE at five concentrations (0%, 0.5%, 1%, 10%, 20% of stock CSE 
medium), and effect on proliferation was determined on days 3 and 14 (Fig. 1A). Proliferation 
was suppressed by CSE (Fig. 1A) in a concentration-dependent manner. Cell viability was also 
determined on days 3 and 14 (Fig. 1B), viability suppression was also concentration-dependent. 
Tropoelastin mRNA levels were significantly decreased in CSE-containing medium at 1% and 
10% compared with control cultures (0%) at 3 and 14 days of culture (Fig. 1C). The decrease in 
mRNA was reflected in significant decreases in levels of soluble tropoelastin (in medium) and 
insoluble (in cell layer) elastin at day 14, with a non-significant trend for both at day 3 (Fig. 1D 
and E). By day 14, soluble elastin in 1% and 10% CSE was decreased by 58% and 64%, and 
insoluble elastin by 49% and 51% respectively. 
3.2. V1 expression increased by CSE and blocked by siRNA 
V1 mRNA levels were significantly increased following 3 days exposure to CSE at 1 and 10% 
(1.9 and 1.7 fold increase respectively compared with control). By day 14, however, this increase 
in mRNA was not significantly raised over control levels (Fig. 2A). Changes in V1 protein levels 
were generally consistent with changes in V1 mRNA. V1 levels in supernatants were 101.8, 127 
and 121.8 ng/106 cells for control, 1% and 10% CSE cultures at day 3, and 21.6, 41.1 and 50.95 
ng/106 cells at day 14. There was no significant difference between cultures exposed to 1% and 
10% CSE (Fig. 2B). The V1 mRNA increase seen in 10% CSE was completely blocked by 
concomitant exposure to V1 siRNA on day 3. On day 14, siRNA reduced V1 mRNA of cells 
exposed to 10% CSE significantly below that of control levels (Fig. 2C), and concomitant culture 
of cells exposed to CSE and siRNA markedly reduced V1 levels in the culture medium (Fig. 2D). 
V1 decreased from 110.7 to 12.5 ng/106 cells on day 3, from 80.4 to 2.3 ng/106 cells on day 14. 
These results demonstrate the effectiveness of V1 knockdown. The scramble siRNA showed no 
knockdown efficacy (Fig. 2C and D). 
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3.3. Effect of V1 knockdown on soluble and insoluble elastin
Exposure of cells to 10% CSE for 3 days did not significantly reduce soluble or insoluble elastin 
levels (Fig. 3A and B), although did show a non-significant decrease similar to initial experiments 
(Fig. 1D and E). On day 14, however, and similar to initial experiments (Fig. 1D and E), both 
soluble and insoluble elastin levels were significantly decreased in 10% CSE. In the concomitant 
cultures on day 3, exposure to CSE plus V1 siRNA did not result in change to soluble or insoluble 
elastin levels (Fig. 3A and B), but at day 14 the siRNA blocked the decrease in insoluble elastin 
seen with CSE alone (Fig. 3B). There was no significant difference in cells transfected with 
scramble siRNA.
3.4. Effect of V1 is via CS
CS in the culture medium was measured to determine whether the effect of versican V1 on 
insoluble elastin was mediated through its CS chains. CS in V1 siRNA treated cultures 
decreased from 1.7 ng/106 cells to 0.4 ng/106 cells by day 3, and from 0.7 ng/106 cells to 0.1 
ng/106 cells by day 14 (Fig. 4A). The addition of exogenous CS to cell culture medium 
significantly decreased insoluble elastin in a concentration-dependent manner over 14 days (Fig.
4B), while the addition of 200 μg/ml of CS in the presence of 10% CSE and V1 siRNA countered 
the protection conferred by the siRNA, resulting in a significant decrease in insoluble elastin (Fig.
4C).
4. Discussion
In the present study we show that CSE applied to cultured human lung fibroblasts, an in vitro
model for COPD, inhibits proliferation, viability and secretion of soluble and insoluble elastin, and 
increases versican variant V1. We further show that the decrease in insoluble elastin induced by 
CSE can be blocked by a siRNA directed at V1, which in turn can be countered by exogenous 
CS, the component of V1 and other CS-rich matrix proteoglycans known to inhibit the deposition 
of insoluble elastin (Hinek et al., 2000; Huang et al., 2006; Black et al., 2008).
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4.1. Cigarette causes poor proliferation ability, viability and elastin lose in fibroblasts
CSE has been shown to repress fibroblast proliferation through re-initiation of mRNA translation 
of CCAAT/enhancer-binding proteins, which coincides with increased interleukin-8 and an 
increase in degraded elastin (Miglino et al., 2012). In a further study, on primary COPD lung 
fibroblasts exposed to CSE at 0.5% and 5% over 72 hours, elastin was not affected. In this 
current study, with CSE levels of 1% and 10%, changes in both soluble and insoluble elastin after 
3 days of exposure were also small and not significant, but were significant at 14 days, which is 
consistent with other studies on elastin production by cultured cells in which insoluble elastin 
takes a week or more to be deposited in significant amounts in the ECM (Black et al., 2008; 
Merrilees et al., 2002). Cigarette smoke induced development of emphysema via the recruitment 
of elastase-producing leukocytes or inactivation of lung elastase-inhibitors (Janoff, 1985). In 
acute stage, neutrophils release elastase which is mainly in charge of the acute insoluble elastin 
degradation, in late stage, matrix metalloproteinase- (MMP-) 12 and MMP-9 secreted by other 
cells (macrophages et al) are involved (Dhami et al., 2000; Churg et al., 2002; Shapiro et al., 
2003; Valenca et al., 2004; Churg et al., 2007). It is reported that cigarette smoke also induces
IFN-gamma-inducible protein-10 release of CD8+ T cells, which induces production of 
macrophage elastase (MMP-12) that degrades elastin (Maeno et al., 2007). Interestingly, CSE is 
expected to have dose-dependent effect on elastin synthesis and deposit. However, in our 
experiment, this effect was not observed, which was consistent with other findings (Chen et al., 
2005; Putnam et al., 2002). Cigarette smoke was a complex compound, different doses of CSE 
might inspire different intracellular signal pathways (Messner et al., 2012). Explanation of this 
phenomenon is still unclear.
4.2. Cigarette stimulates an increase in V1 expression which could be suppressed by siRNA
The mechanism by which CSE stimulates versican production is not clear. It is possible that 
components of CSE act through several enhancers located at the 5’-flanking sequence of 
versican, such as AP2, CCAAT binding transcription factor and SP1 (Naso et al., 1994). In colon 
carcinoma tissue, the versican gene is hypomethylated. This may be another mechanism 
involved in versican overexpression in the CSE model (Adany and Iozzo, 1990). Cigarette smoke 
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also triggers NF-κB-dependent inflammatory responses, (Goncalves et al., 2011; Rom et al., 
2013) which are associated with increases in versican (Wight et al., 2014). Moreover, versican is 
also regulated by several microRNAs (Morton et al., 2008; Wang et al., 2010; Rutnam et al., 
2013). Versican expression, however, has been reported to be inhibited by cadmium chloride, a 
component of CSE (Chambers et al., 2013). Our findings show a significant up-regulation of 
versican by CSE at 3 days, and further up-regulation at 14 days, but with overall lower levels at 
this later time period. The reason for the decrease in versican at day 14 is not clear, but CS 
production is known to decrease with increasing cell density, and this may be a confounding 
factor in how CSE affects versican levels over time (Merrilees, 1987).
4.3 Versican knockdown restores CSE-related loss of insoluble elastin
A reciprocal relationship between versican with constituent CS chains and elastin has been 
reported previously (Wight and Merrilees, 2004), including in lung parenchyma of patients with 
mild to moderate COPD (Merrilees et al., 2008). The increase in versican in the parenchyma of 
COPD lung, and its ability to block formation of elastic fibers may explain why restoration of a 
functional elastic fiber network does not occur in lungs affected by COPD (Merrilees et al., 2008)
or in other emphysematous diseases (Merrilees et al., 2004). It has also been reported that 
versican production is higher in lung fibroblast cells isolated from COPD patients (GOLD stage 
Ⅳ), consistent with the lack of elastic fiber repair and a negative influence on the elastic recoil, 
and suggesting that the relationship exists in patients with severe COPD (Hallgren et al., 2010). A 
caveat to this proposed relationship, however, is that lower levels of versican have been reported 
in distal parenchyma of COPD patients compared with nonsmokers and non-obstructed smokers
even though elastic fiber fractional areas are also low (Annoni et al., 2012). The current 
experimental findings directly, however, support a central role for CS matrix proteoglycans in 
preventing elastic fiber repair and point to manipulation of matrix levels of CS as a possible 
therapeutic strategy for resolving, or slowing progression of COPD.
4.4 Exogenous CS prevents insoluble elastin accumulation 
Our findings show that CSE has significant and reciprocal effects on versican and elastin. These 
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changes under conditions of cell, in which there is an absence of the inflammatory changes seen 
in vivo, point to a key role for versican in inhibiting elastin repair in lungs challenged with 
cigarette smoke. Once versican is knocked down, however, the CSE-induced decrease in 
insoluble elastin is restored. Interestingly, the expression of soluble tropoelastin remains 
depressed. Synthesis and assembly, however, need not be linked in the formation of elastic 
fibers; the final stage of assembly depends on the ECM environment. Both in lung tissue and in 
vessel wall there is evidence that the lack of elastic fibers in damaged or repair tissue is not a 
consequence of reduced synthesis of tropoelastin. Tropoelastin may be expressed at high levels 
but the monomers are not assembled onto the microfibrillar framework. CS has a controlling 
influence on this latter process.
The process of elastic fiber formation involves elastin binding protein that chaperones 
tropoelastin to the cell surface and mediates transfer to the microfibrils. This process is inhibited 
in the presence of CS (Hinek et al., 2000). Elastin binding protein, an inactive variant of 
galactosidase, has a binding pocket for CS which, when occupied, releases tropoelastin 
prematurely and before transfer to the microfibrils (Hinek et al., 2000; Black et al., 2008). A 
consequence of this action is that potential repair of elastic fibers does not take place in the 
presence of elevated levels of pericellular versican or CS, even though cells in repair situations 
still have the capacity to synthesise tropoelastin. In some diseases enhanced synthesis of 
tropoelastin, may occur, as observed by in situ hypridization for alveolar wall fibroblasts in COPD 
(Deslee et al., 2009; Lucey et al., 1998) and for vascular smooth muscle in neointima formed 
following angioplasty (Nikkari et al., 1994). In both situations, however, insoluble elastin is not 
deposited in the ECM. As we demonstrate in this current study, manipulation of versican and or 
CS levels is an effective strategy for modulating elastin deposition by lung fibroblasts.
Study in vivo shows increased versican and corresponding disrupted elastin deposit in COPD 
patients (Merrilees et al., 2008). In rats suffered from balloon injury, the neointimae contains low 
levels versican, increased elastin deposits (Huang et al., 2006). Next, we will study V1 
knockdown effect in vivo.
Therefore, we conclude that targeting versican with siRNA to reduce versican core protein, and 
consequently CS levels, maintains insoluble elastin production in the face of the CSE challenge. 
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Exogenous CS overrides the beneficial effect of siRNA. This result points to a possible 
therapeutic strategy whereby targeting versican may allow for restoration of elastic fibers and 
improved repair of COPD lung.
References
Adany, R., Iozzo, R.V., 1990. Altered methylation of versican proteoglycan gene in human colon 
carcinoma. Biochem Biophys Res Commun. 171, 1402-1413.
Al-Nasiry, S., Geusens, N., Hanssens, M., Luyten, C. Pijnenborg, R., 2007. The use of Alamar 
Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma 
cells. Hum Reprod. 22, 1304-1309.
Ang, L.C., Zhang, Y., Cao, L., Yang, B.L., Young, B., Kiani, C., Lee, V., Allan, K., Yang, B.B., 1999. 
Versican enhances locomotion of astrocytoma cells and reduces cell adhesion through its G1 
domain. J Neuropathol Exp Neurol. 58, 597-605.
Annoni, R., Lancas, T., Tanigawa, R., Matsushita, M., Morais, F.S., Bruno, A., Da Silva, L., 
Roughley, P.J., Battaglia, S., Dolhnikoff, M., Hiemstra, P.S., Sterk, P.J., Rabe, K.F., Mauad, T., 
2012. Extracellular matrix composition in COPD. Eur Respir J. 40, 1362-1373.
Black, P.N., Ching, P.S., Beaumont, B., Ranasinghe, S., Taylor, G., Merrilees, M.J., 2008. 
Changes in elastic fibres in the small airways and alveoli in COPD. Eur Respir J. 31, 998-
1004.
Cattaruzza, S., Schiappacassi, M., Ljungberg-Rose, A., Spessotto, P., Perissinotto, D., Morgelin, 
M., Mucignat, M.T., Colombatti, A., Perris, R., 2002. Distribution of PG-M/versican variants in 
human tissues and de novo expression of isoform V3 upon endothelial cell activation, 
migration, and neoangiogenesis in vitro. J Biol Chem. 227, 47626-47635.
Chambers, R.C., Laurent, G.J., Westergren-Thorsson, G., 1998. Cadmium inhibits proteoglycan 
and procollagen production by cultured human lung fibroblasts. Am J Respir Cell Mol Biol. 19, 
498-506.
Chen, L.J., Zhao, Y., Gao, S., Chou, I.N., Toselli, P., Stone, P., Li, W., 2005. Downregulation of 
lysyl oxidase and upregulation of cellular thiols in rat fetal lung fibroblasts treated with 
cigarette smoke condensate. Toxicol Sci. 83, 372-379.
Page 13 of 21
Ac
ce
pte
d M
an
us
cri
pt
Churg, A., Wang, R., Wang, X., Onnervik, P.O., Thim, K., Wright, J.L., 2007. Effect of an MMP-
9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. 
Thorax. 62, 706-713.
Churg, A., Zay, K., Shay, S., Xie, C., Shapiro, S.D., Hendricks, R., Wright, J.L., 2002. Acute 
cigarette smoke-induced connective tissue breakdown requires both neutrophils and 
macrophage metalloelastase in mice. Am J Respir Cell Mol Biol. 27, 368-374.
Deslee, G., Woods, J.C., Moore, C.M., Liu, L., Conradi, S.H., Milne, M., Gierada, D.S., Pierce, J., 
Patterson, A., Lewit, R.A., Battaile, J.T., Holtzman, M.J., Hogg, J.C., Pierce, R.A., 2009. 
Elastin expression in very severe human COPD. Eur Respir J. 34, 324-331.
Dhami, R., Gilks, B., Xie, C., Zay, K., Wright, J.L., Churg, A., 2000. Acute cigarette smoke-
induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-
antitrypsin. Am J Respir Cell Mol Biol. 22, 244-252.
Dours-Zimmermann, M.T., Maurer, K., Rauch, U., Stoffel, W., Fassler, R., Zimmermann, D.R., 
2009. Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the 
CNS. J Neurosci. 29, 7731-7742.
Fink, L., Seeger, W., Ermert, L., Hanze, J., Stahl, U., Grimminger, F., Kummer, W., Bohle, R.M., 
1998. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med. 4, 1329-1333.
Goncalves, R.B., Coletta, R.D., Silverio, K.G., Benevides, L., Casati, M.Z., Da Silva, J.S., Nociti, 
F.J., 2011. Impact of smoking on inflammation: overview of molecular mechanisms. Inflamm 
Res. 60, 409-424.
Hallgren, O., Nihlberg, K., Dahlback, M., Bjermer, L., Eriksson, L.T., Erjefalt, J.S., Lofdahl, C.G., 
Westergren-Thorsson, G., 2010. Altered fibroblast proteoglycan production in COPD. Respir 
Res. 11, 55. 
Hinek, A., Mecham, R.P., Keeley, F., Rabinovitch, M., 1991. Impaired elastin fiber assembly 
related to reduced 67-kD elastin-binding protein in fetal lamb ductus arteriosus and in cultured 
aortic smooth muscle cells treated with chondroitin sulfate. J Clin Invest. 88, 2083-2094.
Hinek, A., Smith, A.C., Cutiongco, E.M., Callahan, J.W., Gripp, K.W., Weksberg, R., 2000. 
Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are 
related to functional deficiency in the 67-kD elastin-binding protein. Am J Hum Genet. 66, 
Page 14 of 21
Ac
ce
pte
d M
an
us
cri
pt
859-872.
Huang, R., Merrilees, M.J., Braun, K., Beaumont, B., Lemire, J., Clowes, A.W., Hinek, A., Wight, 
T.N., 2006. Inhibition of versican synthesis by antisense alters smooth muscle cell phenotype 
and induces elastic fiber formation in vitro and in neointima after vessel injury. Circ Res. 98, 
370-377.
Janoff, A., 1985. Elastases and emphysema. Current assessment of the protease-antiprotease 
hypothesis. Am Rev Respir Dis. 132, 417-433.
Lucey, E.C., Goldstein, R.H., Stone, P.J., Snider, G.L., 1998. Remodeling of alveolar walls after 
elastase treatment of hamsters. Results of elastin and collagen mRNA in situ hybridization. 
Am J Respir Crit Care Med. 158, 555-564.
Maeno, T., Houghton, A.M., Quintero, P.A., Grumelli, S., Owen, C.A., Shapiro, S.D., 2007. CD8+ 
T Cells are required for inflammation and destruction in cigarette smoke-induced emphysema 
in mice. J Immunol. 178, 8090-8096.
Maclay, J.D., McAllister, D.A., Rabinovich, R., Haq, I., Maxwell, S., Hartland, S., Connell, M., 
Murchison, J.T., Beek, E.J., Gray, R.D., Mills, N.L., Macnee, W., 2012. Systemic elastin 
degradation in chronic obstructive pulmonary disease. Thorax. 67, 606-612.
Merrilees, M.J.,1987. Synthesis of glycosaminoglycans and proteoglycans. In: Vascular Smooth 
Muscle in Culture. Eds. JH Campbell and GR Campbell, CRC Press, Boca Raton, Florida 
1987; 133-151.
Merrilees, M.J., Ching, P.S., Beaumont, B., Hinek, A., Wight, T.N., Black, P.N., 2008. Changes in 
elastin, elastin binding protein and versican in alveoli in chronic obstructive pulmonary 
disease. Respir Res. 9, 41. 
Merrilees, M.J., Hankin, E.J., Black, J.L., Beaumont, B., 2004. Matrix proteoglycans and 
remodelling of interstitial lung tissue in lymphangioleiomyomatosis. J Pathol. 203, 653-660.
Merrilees, M.J., Lemire, J.M., Fischer, J.W., Kinsella, M.G., Braun, K.R., Clowes, A.W., Wight, 
T.N., 2002. Retrovirally mediated overexpression of versican v3 by arterial smooth muscle 
cells induces tropoelastin synthesis and elastic fiber formation in vitro and in neointima after 
vascular injury. Circ Res. 90, 481-487.
Messner, B., Frotschnig, S., Steinacher-Nigisch, A., Winter, B., Eichmair, E., Gebetsberger, J., 
Page 15 of 21
Ac
ce
pte
d M
an
us
cri
pt
Schwaiger, S., Ploner, C., Laufer, G., Bernhard, D., 2012. Apoptosis and necrosis: two 
different outcomes of cigarette smoke condensate-induced endothelial cell death. Cell Death 
Dis. 3, e424.
Miglino, N., Roth, M., Lardinois, D., Sadowski, C., Tamm, M., Borger, P., 2012. Cigarette smoke 
inhibits lung fibroblast proliferation by translational mechanisms. Eur Respir J. 39, 705-711.
Morton, S.U., Scherz, P.J., Cordes, K.R., Ivey, K.N., Stainier, D.Y., Srivastava, D., 2008. 
microRNA-138 modulates cardiac patterning during embryonic development. Proc Natl Acad 
Sci U S A. 105, 17830-17835.
Muller, T., 1995. Expression of c-fos in quiescent Swiss 3T3 cells exposed to aqueous cigarette 
smoke fractions. Cancer Res. 55, 1927-1932.
Naso, M.F., Zimmermann, D.R., Iozzo, R.V., 1994. Characterization of the complete genomic 
structure of the human versican gene and functional analysis of its promoter. J Biol Chem.
269, 32999-33008.
Nikkari, S.T., Jarvelainen, H.T., Wight, T.N., Ferguson, M., Clowes, A.W., 1994. Smooth muscle 
cell expression of extracellular matrix genes after arterial injury. Am J Pathol. 144, 1348-1356.
Putnam, K.P., Bombick, D.W., Doolittle, D.J., 2002. Evaluation of eight in vitro assays for 
assessing the cytotoxicity of cigarette smoke condensate. Toxicol In Vitro. 16, 599-607.
Rom, O., Avezov, K., Aizenbud, D., Reznick, A.Z., 2013. Cigarette smoking and inflammation 
revisited. Respir Physiol Neurobiol. 187, 5-10.
Rutnam, Z.J., Wight, T.N., Yang, B.B., 2013. miRNAs regulate expression and function of 
extracellular matrix molecules. Matrix Biol. 32, 74-85.
Sampson, P.M., Boyd, R.B., Pietra, G.G., Fishman, A.P., 1984. Glycosaminoglycan biosynthesis 
in the isolated perfused rat lung. J Appl Physiol Respir Environ Exerc Physiol. 57, 1648-1654.
Schonherr, E., Jarvelainen, H.T., Sandell, L.J., Wight, T.N., 1991. Effects of platelet-derived 
growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like 
chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem. 266, 17640-
17647.
Shapiro, S.D., Goldstein, N.M., Houghton, A.M., Kobayashi, D.K., Kelley, D., Belaaouaj, A., 2003. 
Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol.
Page 16 of 21
Ac
ce
pte
d M
an
us
cri
pt
163, 2329-2335.
Snider, G.L., 2000. Clinical relevance summary: Collagen vs elastin in pathogenesis of 
emphysema; cellular origin of elastases; bronchiolitis vs emphysema as a cause of airflow 
obstruction. Chest. 117, 244S-6S.
Valenca, S.S., Hora, K., Castro, P., Moraes, V.G., Carvalho, L., Porto, L.C., 2004. Emphysema 
and metalloelastase expression in mouse lung induced by cigarette smoke. Toxicol Pathol. 32, 
351-356.
Wang, X., Hu, G., Zhou, J., 2010. Repression of versican expression by microRNA-143. J Biol 
Chem. 285, 23241-23250.
Wight, T.N., 2002. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin 
Cell Biol. 14, 617-623.
Wight, T.N., Kinsella, M.G., Evanko, S.P., Potter-Perigo, S., Merrilees, M.J., 2014. Versican and 
the regulation of cell phenotype in disease. Biochim Biophys Acta. 1840, 2441-2451.
Wight, T.N., Merrilees, M.J., 2004. Proteoglycans in atherosclerosis and restenosis: key roles for 
versican. Circ Res. 94, 1158-1167.
Wu, Y., Chen, L., Zheng, P.S., Yang, B.B., 2002. beta 1-Integrin-mediated glioma cell adhesion 
and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-
M/versican. J Biol Chem. 277, 12294-12301.
Wu, Y.J., Pierre, D.P., Wu, J., Yee, A.J., Yang, B.B., 2005. The interaction of versican with its 
binding partners. Cell Res. 15, 483-494.
Yang, B.L., Zhang, Y., Cao, L., Yang, B.B., 1999. Cell adhesion and proliferation mediated 
through the G1 domain of versican. J Cell Biochem. 72, 210-220.
Zhang, J., Wu, L., Qu, J.M., Bai, C.X., Merrilees, M.J., Black, P.N., 2012. Pro-inflammatory 
phenotype of COPD fibroblasts not compatible with repair in COPD lung. J Cell Mol Med. 16, 
1522-1532.
Page 17 of 21
Ac
ce
pte
d M
an
us
cri
ptFigure legendsFigure 1 Effect of CSE on fibroblast proliferation, viability and elastin expression and deposition. 
A Proliferation indices, determined by Alarma Blue assay, for control and CSE exposed 
cultures at 3 (left) and 14 (right) days. B The effect of CSE (0-20%) on cell viability is 
delineated. Cell viability decreased with raised concentrations. C Fold change in elastin 
mRNA in fibroblast cultures exposed to CSE, calculated as experimental 2-ddCt/control 2-
ddCt－1. D and E Effect of CSE on soluble and insoluble elastin production by fibroblasts 
cultured for 3 and 14 days. *, p<0.05; **, p<0.01.
Figure 2 Effect of CSE and V1 siRNA on expression and secretion of versican V1 by cultured 
lung fibroblasts. A Fold difference from control cultures for V1 mRNA expression at 3 and 14 
days. B V1 levels in medium at 3 and 14 days. C Effect of V1 siRNA (80nM) on V1 expression 
at 3 and 14 days, expressed as fold difference from control cultures. D Effect of V1 siRNA on 
V1 levels in medium at 3 and 14 days. *, p<0.05; **, p<0.01; ***, p<0.001.
Figure 3 Effect of V1 siRNA (80nM) on soluble and insoluble elastin. A and B Effect of V1 siRNA 
on soluble (A) and insoluble (B) elastin levels produced by lung fibroblasts cultured for 3 and 
14 days and exposed to 10% CSE. *, p<0.05.
Figure 4 V1 siRNA restored insoluble elastin repair was countered by chondroitin sulfate (CS). A 
Effect of V1 siRNA on CS levels in medium of fibroblasts cultured for 3 and 14 days and 
exposed to 10%CSE. B Effect of exogenous CS on production of insoluble elastin by lung 
fibroblasts cultured for 14 days. C Effect of exogenous CS on V1 siRNA-treated control (0% 
CSE) and CSE (10%) exposed fibroblasts cultured for 14 days. *, p<0.05; **; p<0.01.
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